Feldon Lab
Welcome to the Feldon Lab
Research Overview
Multidisciplinary collaborations are a key to the successful enhancement of eye health. The University of Rochester Medical Center and the Flaum Eye Institute provide an ideal environment for this work.
Graves' Disease
One example of current multidisciplinary investigations is the Graves’ disease collaboration between Steven E. Feldon, M.D., an orbital disease specialist, and Collynn Woeller, Ph.D., a researcher who specializes in the study of the biology of fibroblasts (connective tissue cells involved in thyroid eye disease).
Many Graves’ disease patients—especially women who smoke—will develop thyroid eye disease, a condition that causes disfiguring bulging eyes, corneal drying, optic nerve inflammation, blurry vision, and even blindness. An inflammatory process associated with the disease induces structural cells behind the eye called fibroblasts to make too much connective tissue protein. The fibroblasts also convert into fat-like cells. The combination of excessive connective tissue and accumulating fatty tissue pushes the eye out of the eye socket, causing disfigurement, double vision, and vision loss.
Steven Elliott Feldon, M.D., M.B.A.
Principal Investigator
Publications
View All Publications- Tapinarof, an Aryl Hydrocarbon Receptor Ligand, Mitigates Fibroblast Activation in Thyroid Eye Disease: Implications for Novel Therapy.; Investigative ophthalmology & visual science; Vol 65(13), pp. 40. 2024 Nov 04.
- Vision-related quality of life after unilateral occipital stroke.; Brain and behavior; Vol 14(7), pp. e3582. 2024 Jul.
- Training in Cortically Blinded Fields Appears to Confer Patient-Specific Benefit Against Retinal Thinning.; Investigative ophthalmology & visual science; Vol 65(4), pp. 29. 2024 Apr 01.
- Training in cortically-blind fields confers patient-specific benefit against retinal thinning after occipital stroke.; medRxiv : the preprint server for health sciences. 2023 Dec 20.
- Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease.; The Journal of clinical endocrinology and metabolism. 2023 Jun 30.
Contact Us
Feldon Lab
601 Elmwood Ave, Box 659
Rochester, NY 14642
(585) 506-0292